Saxenda approved as the first GLP-1 for weight management

Liraglutide 3 mg, sold as Saxenda, has been approved for chronic weight management in adults, making it the first glucagon-like peptide-1 (GLP-1) receptor agonist cleared in the United States for obesity rather than diabetes. Federal drug listing data show the product under application NDA 206321, as a 6 mg/mL subcutaneous injection classified as a GLP-1 receptor agonist, with a listed marketing start date of December 31, 2014 ^[1].

The significance is as much about the dose as the molecule. Liraglutide was already marketed at lower daily doses for type 2 diabetes. Saxenda took the same drug to 3.0 mg once daily and tested it in people without diabetes, establishing that a diabetes drug class could be pushed higher and studied specifically for weight loss — the path later followed by semaglutide (Wegovy) and tirzepatide (Zepbound).

What the pivotal trial showed

The key study was SCALE Obesity and Prediabetes (NN8022-1839, ClinicalTrials.gov NCT01272219), a 56-week, double-blind trial in 3,731 patients without type 2 diabetes who had a body-mass index of at least 30, or at least 27 with treated or untreated high cholesterol or high blood pressure ^[2]. Participants were randomly assigned 2:1 to once-daily subcutaneous liraglutide 3.0 mg (2,487 patients) or placebo (1,244 patients). Both groups received counseling on lifestyle changes ^[2].

At the start, the average age was 45.1 years, average weight was 106.2 kg (about 234 pounds), and average BMI was 38.3. Women made up 78.5% of participants, and 61.2% had prediabetes ^[2].

At week 56, the liraglutide group had lost an average of 8.4 kg (roughly 18.5 pounds) versus 2.8 kg (about 6.2 pounds) on placebo — a difference of 5.6 kg, with a 95% confidence interval of 6.0 to 5.1 kg and P<0.001 using last-observation-carried-forward imputation ^[2]. A total of 63.2% on liraglutide lost at least 5% of their starting weight, compared with 27.1% on placebo, and 33.1% versus 10.6% lost more than 10% ^[2].

The most frequently reported side effects with liraglutide were mild or moderate nausea and diarrhea. Serious adverse events occurred in 6.2% of the liraglutide group and 5.0% of the placebo group ^[2]. The trial was funded by Novo Nordisk, the drug's maker ^[2].

Why it matters for patients

Before this approval, weight-management drug options did not include the GLP-1 class. Saxenda's clearance created a regulatory precedent: the same active ingredient, at a higher dose and with its own trial program and application number, can be approved for a different condition under a different brand name ^[1]. That is exactly the structure patients now see with Ozempic and Wegovy (both semaglutide) and Mounjaro and Zepbound (both tirzepatide). It also matters for insurance, because coverage often follows the approved indication on the label rather than the molecule itself.

The SCALE numbers are also a useful benchmark for judging newer drugs. An average loss of about 8% of body weight at roughly one year, with about a third of patients losing more than 10%, set the bar that later GLP-1 and dual-agonist medicines were measured against ^[2]. The trial's design is worth noting too: everyone got lifestyle counseling, and the placebo group still lost 2.8 kg, so the drug-specific effect was the 5.6 kg difference, not the full 8.4 kg ^[2].

The trial also shows what a 56-week study can and cannot answer. It measured weight, and reported gastrointestinal side effects as the most common problem ^[2]. Longer-term outcomes such as heart attacks or strokes were not among the results reported in this trial's primary findings, and are not addressed in the sources here.

What is not yet known from these sources

The FDA approval letter, the full prescribing information including warnings and the dose-escalation schedule, the US list price, and insurance coverage decisions are not contained in the documents reviewed for this report. The drug listing record notes that openFDA data are unvalidated and should not be used to make medical decisions ^[1].